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PREAMBLE 
 
Welcome to the Development and User manual for the Maudsley 
Addiction Profile.   The MAP is a brief, structured interview for 
treatment outcome research. 
 
This document is in four parts: 
 
Part I: Describes the rationale and development of the instrument. 
 
Part II: Summarises how to administer the MAP and contains 
suggestions on good interviewing practice. 
 
Part III: Presents the results of the field-testing of the instrument 
and its psychometric characteristics. 
 
Part IV: Shows an example MAP instrument which can be 
photocopied or adapted as required. 
 
 
The authors welcome comments on the instrument and the User 
Manual.  Please direct comments to  
 
J.Marsden@iop.kcl.ac.uk  
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PART I :  INTRODUCTION AND USING THE INSTRUMENT  
 
The MAP is a brief, interviewer administered questionnaire for treatment outcome 
research applications.  It measures problems in four domains: substance use, health 
risk behaviour, physical and psychological health, and personal/social functioning.  
The MAP is the first brief questionnaire to be developed in the UK for assessing these 
domains with people with drug and alcohol problems. It is designed as a core 
research instrument and to be a resource for treatment services wishing to undertake 
outcome studies.  For most subjects, interview completion time is approximately 12 
minutes.   The MAP is a public domain research instrument and may be used free of 
charge for not-for-profit applications.  Users are asked to cite the following 
reference when using the instrument: 
 
Marsden, J. Gossop, G. Stewart, D. Best, D. Farrell, M. Lehmann, P. Edwards, 
C. & Strang, J. (1998) The Maudsley Addiction Profile (MAP): A brief 
instrument for assessing treatment outcome, Addiction 93(12): 1857-
1867. 
 
We have designed the MAP explicitly for outcome research purposes. All of the 
problem measures can be repeatedly administered at points during and after an 
index treatment episode. Changes in these measures can then be attributed to 
treatment or other processes over the intervening period.  A key principle behind the 
MAP is that, as a core instrument, other measures and items can be added as 
required according to clinical, operational or research requirement.  For example, a 
measure of drug dependence could be included, as well as questions concerning drug 
use history.   
 
Rat iona le 
The rationale for the development of the MAP concerns the increased recognition in 
the UK of the importance of extending research on the outcome of treatment for 
substance use problems (Task Force to Review Services for Drug Misusers 1996).   
Significantly, the national strategy on drug misuse has prioritised the expansion of 
outcome research and performance monitoring of treatment services (Tackling Drugs 
to Build a Better Britain, 1998).  In the United States the value of gathering data on 
treatment outcome has been widely promoted across the present decade (Institute of 
Medicine 1990; Center for Substance Abuse Treatment 1995) and several systems 
have been developed (e.g. Harrison et al. 1996; Dennis, et al. 1998).  In the UK 
progress towards expanding outcome research efforts is at an early stage.  Launched 
in 1995, the on-going National Treatment Outcome Research Study (NTORS) has 
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advanced understanding of outcomes for people entering community methadone 
prescribing services and residential programmes.  Little systematic work has been 
undertaken in other treatment modalities and settings.   In particular, little priority 
has been given to developing valid and reliable instruments to assess treatment 
outcome.  One obstacle to implementing outcome studies has been the lack of 
consensus about what constitutes a minimum outcomes data set.   
 Against this background, we saw the need for a new instrument for assessing 
treatment outcome, which could provide a minimum outcome data set.  Omnibus 
instruments for treatment research have been developed in other countries (e.g. 
Addiction Severity Index, ASI, McLellan et al. 1980; McLellan et al. 1992a; and Opiate 
Treatment Index, OTI, Darke et al. 1992).  Partly because of their completion time 
(approximately 45 minutes), these have not been widely used in the UK.  Given the 
importance of minimising the administrative burden on treatment personnel we 
considered there to be important benefits from developing a brief, core instrument 
for outcome research.    
 
In i t i a l  deve lopment 
The content-related validity of the items for the MAP was specifically informed from 
the outcome domain areas used by a Department of Health Task Force (Task Force on 
Services for Drug Misusers, 1995) based on recommendations from Marsden 1994 
and from the development and implementation of a wider set of outcome measures 
for the National Treatment Outcome Research Study (NTORS)(Marsden et al., 1998).  
The items for the instrument were also informed by relevant outcome instruments 
and outcome monitoring (e.g. McLellan et al., 1995; Darke at al., 1992; Simpson & 
Chatham 1995; Dennis, et al. in press).   
 In the field-tested version of the MAP, the subject’s recall period is the past 30 
days (one month) before the entering an index treatment.    As far as possible, we 
have sought to incorporate continuous measures with a common metric.  For 
example, the measures of frequency of behaviour can be expressed in percentage 
terms (e.g. percent of days used heroin; percent days in conflict with partner; percent 
days employed) and these indicators can be clearly interpreted.  Categorical 
measures can also be calculated at follow-up to describe substance use (e.g. the 
proportion of a sample that are abstinent, infrequent, regular, and daily users) as well 
as the percentage of subjects who report injecting, sharing needles/syringes, 
employment and crime.  At this initial stage in the development of the MAP, 
pretreatment means for the physical and psychological health scales can be used to 
contrast mean scores for individuals and samples measured in future studies.   
Changes in severity estimates for individual items may also be valuable single 
indicators of treatment benefit (for example, the frequency of suicidal ideation from 
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the depression sub-scale).  Please note that although the MAP records problems in 
key areas, that these problems are not necessarily caused or attributed by the subject 
to his/her use of drugs or alcohol.  The subject is not asked to attribute whether 
problems have been due to or caused by their substance use behaviour. 
 
Prac t i ca l  app l i ca t ions  
In practical usage, we recommend that a modular approach to outcome research is 
adopted in which a primary set of outcome measures is recorded, with other outcome 
measures included as required. This would allow for a core set of measures to be 
gathered across different programmes to facilitate the communication of results, 
whilst promoting flexibility in the set of outcome measures collected.  Assessment 
could also incorporate measures of direct and indirect needle/syringe sharing 
practices, using for example the Injecting Risk Questionnaire (Stimson, et al., 1998).  
We have also recently developed the Treatment Perceptions Questionnaire (TPQ, 
Marsden et al., 1998),  a brief 10-item measure of addiction treatment satisfaction, 
which can be used as an adjunct to the core MAP instrument as required.  Other 
measures of personal and environmental supports and stressors using existing 
instruments may be usefully added.  Measures of treatment itself are also required 
and there are several instruments available which record different aspects of 
treatment processes and programme environment  (Simpson & Chatham 1995; Moos 
1988b; McLellan et al. 1992b).  As a minimum, the setting, modality and duration of 
treatment should be recorded.  Additional measures of a client’s choice of treatment 
goals, the amount of programme services received, the financial cost of programme 
services received, treatment discharge s tatus and additional non-index treatments 
received, could also be used in a comprehensive outcome evaluation.   
 
Prob lem domains  assessment  by  the  MAP  
Attenuation or cessation of drug and/or alcohol consumption is the obvious primary 
indicator of success for this treatment population.  Individuals entering treatment 
may also  suffer from chronic and/or acute medical, psychological and social 
difficulties.  Reflecting this, research studies have used an increasingly broad array of 
problem measures and outcome evaluations and analyses have become multi-
dimensional (eg. McLellan et al. 1980; Taylor et al. 1985; Simpson, Joe & Lehman 
1986; Moos, Finney & Cronkite 1990).  Three problem domains are usually assessed:  
(a) drug and alcohol consumption; (b) health problems; and (c) personal/social 
functioning; the latter usually spanning relationship problems, employment and 
crime involvement (McLellan et al. 1980; Babor et al. 1994; Simpson & Chatham 
1995).  Since the mid 1980s, the risk of exposure of drug injectors to the Human 
Immunodeficiency Virus (HIV) and other blood-borne infections (eg. Hepatitis B and C 
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viruses) has led to the important addition of a fourth domain concerning injecting 
and other health risk behaviours (Strang 1992).  Measures of outcome from these 
four domains are described in the following section. 
 
Substance  use 
There is now broad agreement that treatment outcome studies should record, as a 
minimum, the frequency of use of different substances in 24-hour intervals during a 
recall period and the intensity of daily consumption (Wells, Hawkins & Catalano 1988; 
Addiction Research Foundation 1993; Babor et al. 1994).  These measures reflect the 
likelihood of harm to the user arising when substances are consumed either with 
high frequency and/or high intensity (ie. large amounts consumed on a single 
occasion).  In addition it is important to record whether a substance is taken by 
medical prescription and also the route(s) used for its administration (ie. oral, 
intranasal, inhalation and injection).  
 For alcohol, consumption is usually reported by ethanol content, by weight or 
fluid volume (Miller, Heather & Hall 1991).  In contrast, measuring the content of 
illicit drugs doses can be  problematic.  Outcome research in the US has tended to 
focus on frequency rather than intensity measures because of concerns about the 
accuracy of self-reports of drug purity and the size of drug doses. Nevertheless, an 
estimate of the usual quantity consumed of used substances is a desirable additional 
clinical and research measure, not least because at follow-up an individual may have 
maintained the same frequency of use but achieved a marked reduction in their 
intensity of consumption. In the UK, concerns over the accuracy of self-reported illicit 
drug content are offset to some extent by data showing that purity levels of retail 
seizures of illicit heroin and cocaine have been broadly constant for many years (King 
1997; Strang, Griffiths & Gossop 1997).   
 
Hea l th  r isk  behav iour  
Injecting drug users may be exposed to blood borne infections through the “sharing” 
of infected needles/syringes, and potentially through the sharing of certain items 
used in injection procedures (Gossop et al. 1997b).   Assessments of the frequency of 
injecting, sharing and other injecting risk behaviours are acknowledged to be 
important outcome measures of service interventions.  At the population level, HIV is 
mainly transmitted through sexual intercourse.  Since many substance users are 
sexually active, the assessment of penetrative sexual behaviour without condom use 
is also an important measure of risk of viral exposure (McKeganey, Bernard & Waston 
1989; Magura et al. 1990; Donoghoe 1992). 
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Phys ica l  and psycho log ica l  hea l th   
There are a variety of physical and psychological health disorders which may be 
linked to or concurrent with problem substance use (Wartenberg 1994; Rubin & 
Benzer 1997).  Of all the psychological disorders, a high prevalence of anxiety and 
depressive thoughts of a transient or chronic nature have most commonly been 
reported amongst substance users in treatment (eg. Rounsaville et al. 1982; Ross, 
Glaser & Germanson 1988).  The management of physical and psychological health 
problems is a common activity in many treatment programmes.  However, there has 
been relatively less attention to developing and assessing physical and psychological 
health symptoms in substance using treatment populations as outcome measures. 
 
Persona l/soc ia l  funct ion ing  
In this broad domain, three areas are usually assessed: (i) Relationship conflicts and 
problems.  Treatment programmes broadly aim to encourage improved relations 
between a subject and his/her sexual partner, family and friends.  Conflict in these 
areas has been shown to exert an important negative predictor of outcome (Moos, 
Fenn & Billings 1988a).  (ii) Employment.  Involvement in a paid job has been found to 
be a predictor of retention in treatment and good outcome (Simpson, Joe & Lehman 
1986).  Although the ability of a treatment programme to secure a job for a subject 
may be limited, community services will usually seek to support a subject to improve 
employment opportunities, and securing or maintaining a job is recognised to be an 
important goal (French et al. 1992).  (iii) Criminal activity.   For some individuals, 
crime is an instrumental means of funding drug use (Jarvis & Parker 1989; Hough 
1996).  A reduction in criminal involvement is an important public safety benefit from 
treatment, and the number of property crimes (particularly shoplifting, the most 
frequent property crime), drug-selling and other acquisitive crimes are usually 
recorded by outcome studies (eg. Anglin & Speckart 1988).  
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STRUCTURE OF THE MAP  
 
The 30-day period before intake to treatment was used as the recall period for the 
MAP interview.  This period has been used in a variety of research instruments (e.g. 
McLellan et al. 1992a; Simpson & Chatham 1995) and is a compromise between a 
shorter period (such as seven days) which may fail to capture episodic substance use 
and other behaviour, and a longer period (such as six months) where a subject may 
be more likely to experience recall problems. 
 
St ructure  of  the  f ie ld  tes ted vers ion of  the  inst rument 
The Following an introductory section the MAP contains 60 items in four domains.  
 
(a )  Substance  use .   Assessment was limited to five substance types which are 
associated with clinical problems amongst our clients at the Maudsley Hospital and 
which are broadly representative of the substances which are currently used by the 
treatment seeking population in the UK: illicit heroin, non-prescribed methadone and  
benzodiazepines (usually diazepam and temazepam), cocaine hydrochloride, cocaine 
base (crack) and alcohol.  For use in other settings and countries the substitution or 
addition of other psychoactive substances to the MAP may be required.   The total 
number of days of use for a substance before intake is recorded first.  The subject is 
shown a response card with seven common frequency patterns (ranging from “one 
day per week” to “every day”) and is asked which of these summarises the frequency 
of their use.  The corresponding number of days is then recorded.  For substances 
used on an episodic basis, or when there is no typical pattern, the interviewer uses a 
calendar to prompt recall of the last day that substance was used. This day and any 
previous days during the recall period is recorded.  Intensity of substance use is 
assessed from the verbatim report of the amount consumed on a typical using day in 
the past month (usually given by weight or by retail price, with prompting as 
required).  For alcohol, consumption on a typical drinking day is assessed in terms of 
beverage types, strength of alcohol content and the number and sizes of drinks.  
Self-reports are recorded verbatim and later converted into standardised units of 
ethanol (1 unit = 8g -10g; 0.28- 0.35 ounces).  In instances where the quantity of 
alcohol or other substances consumed has varied, the subject is asked to recall the 
amount used on the two-three most recent days of use during the recall period. 
These are recorded verbatim and later averaged.  With the exception of alcohol, the 
usual route(s) of administration is recorded using the following categories: oral, 
intranasal, inhalation and injection.  
 
(b )  Heal th  r isk  behav iour .  The number of days on which the subject injected drugs 
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and the number of injections on a typical day is recorded first.  Episodic injecting 
patterns are recorded using the same procedure described above.  The subject is also 
asked about the number of times they have injected using a needle/syringe which 
they believe has already been used by someone else.  For sexual intercourse, the 
subject is asked to estimate the number of people and the number of times in total 
that they have had penetrative sex and not used a condom.  
 
( c )  Hea l th  symptoms.    
Phys ica l 
A 10-item physical health symptom scale was adapted from a 51-item checklist from 
the Opiate Treatment Index (Darke et al. 1991).  Treatment intake data from the OTI 
health scale for 1075 participants in NTORS was used to reduce the number of 
original items.  The drug injecting-related items were removed to make the new scale 
jointly applicable to drug users (DUs) and alcohol users (AUs).  Ten items were 
removed using a criterion of 20% or less of NTORS participants reporting each 
symptom in the past 90 days before intake to treatment. Dental problems and loss of 
sex urge were reported by 54% and 63% of the sample, respectively.  We elected to 
remove these from the new item pool because of a lack of fit with items in the other 
functional systems.   Spearman’s rho rank-order correlations were computed for each 
of the retained pairs of items from each section.  Correlations between any two pairs 
did not exceed 0.41.  In each section with more than two items, the pair with the 
highest rank order correlations were selected. The final five functional systems, 
component items and rank order correlations (p < .0001) are: general (poor appetite 
and tiredness/fatigue), r = 0.31); cardio-respiratory (chest pains and difficulty 
breathing),  r = 0.39); gastro-intestinal (nausea and stomach pains), r = 0.38); 
neurological (tremors/shakes and numbness/tingling),  r = 0.41); and musculo-
skeletal (joint pain/stiffness and muscle pain), r = 0.32).  A five-point Likert-type 
scale was included to assess the frequency of experiencing each symptom using the 
following expressions: never, rarely, sometimes, often, always (scored 0-4).  The 
scale is scored by summing the weights 0-4 across the 10 items. Internal reliability of 
the scale was satisfactory (alpha =  0.77).  
 
Psycho log ica l 
A 10-item scale to assess psychological health symptoms was also derived from the 
two six-item anxiety and depression sub-scales of the Brief Symptom Inventory (BSI, 
Derogatis 1975).  Intake data from selected sub-scales from the BSI as used in 
NTORS  was utilised to adapt scale items for the MAP.  Internal reliability of the 
anxiety sub-scale was increased to 0.88 by the removal of one item (“feeling you 
could not sit still”).  The five retained items are as follows: “Feeling tense and keyed 
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up”; “suddenly scared for no reason”; “feeling fearful”’; “nervousness or shakiness 
inside”; and,  “spells of terror or panic”.  For the depression sub-scale, an initial item 
from the BSI, “feeling blue”, was judged to be an expression in limited contemporary 
use in the UK and was removed.  The internal reliability of the five items was 
satisfactory (alpha = 0.81).  The retained items are: “Feeling hopeless about the 
future”; “feelings of worthlessness”; " feeling no interest in things”; “feeling lonely”; 
“thoughts of ending your life”.  A five point Likert-type anchoring (never - always) is 
again used for the overall 10-item psychological health scale. 
 
(d) Personal/Social functioning. The final domain contains nine items in three areas:  
 
(i) Relationship conflict.  A  measure of conflict in personal relationships was taken by 
recording the number of days on which the subject had contact with his/her sexual 
partner, relative(s) and friends and the number of days on which there had been 
serious conflict.  These are based on measures of family conflict developed for the 
Addiction Severity Index (McLellan et a l. 1992a).   The MAP extends the original ASI 
items by enquiring first about the amount of time the client has spent with their 
partner, relatives and friends relationship conflict.  Contact is defined as face-to-face 
interactions or telephone calls.  Serious conflict is defined as major arguments, verbal 
abuse and/or violence, but not routine differences of opinion.  If the subject was not 
in a personal sexual relationship, or did not have relatives or friends, a score of zero 
is recorded reflecting no conflict on these measures.   
 
(ii) Employment .  Three measures of employment are taken: the number of days of 
formal unemployment; the number of days on which the subject undertook paid 
work; and the number of working days on which the subject did not attend work due 
to sickness or unauthorised absence.   
 
(iii) Cr imina l  behav iour.   Three categories of criminal activity are recorded: sales of 
illegal drugs, shoplifting, and “other crime” - including theft from a property, theft 
from a person, theft from or of a vehicle, and fraud/forgery.  The number of days and 
times on a typical day on which each crime type was committed is recorded.  
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PART 11: ADMINSTRATION AND SCORING 
 
In this section, we describe how to use and score the MAP for research and outcome 
monitoring applications.    In this section, notes on scoring the instrument are shown 
in highlighted boxes.  An example of the questionnaire is shown in Part IV (page 37).  
This example contains the core items of the instrument and has a front sheet with 
various management and operational measures.  In practice, these will need to be 
tailored to the needs of the particular application and/or treatment setting.  
Additional measures which may need to be included are: presence of additional 
health disorders, case re-referral information; treatment funding issues (and duration 
of episode if known).   The structure of the MAP instrument shown is follows:  
 
Section Item 
A: Management Information Programme setting, client demographics ,  
non-attributable identifiers and referral details 
B: Substance use Number of days used substances  
Typical amount used per day when using 
Main route(s) of administration 
C: Health risk behaviour Days injected  
Typical times injected per day 
Times sharing needles or syringes        
Number of sexual partners when not using condom 
Times had sex without using condom 
D: Health symptoms Frequency of physical symptoms 
Frequency of psychological symptoms 
E: Personal /social functioning Days contact/conflict partner, relative, friends 
Days had paid job.  
Days missed (sickness/unauthorised )                              
Days unemployed  
Days committed illegal activities; times/day            
 
It is important to understand the purpose of each question, and we recommend 
thorough study of the MAP in advance.  This is particularly important when clarifying 
areas of uncertainty or confusion for a subject. When using the MAP for the first few 
times, it is advisable to include specific question wording for preambles to sections 
and specific items and to read these out to the subject.   As interviewers become 
familiar with the structure and will want to use personal phrasing to introduce each 
section and specific question.  Naturally, it is very important to retain the same 
meaning of the original items to maximise the validity and reliability of the interview. 
 It is also very important to ensure that all the questions are completed.  
However, if, the subject refuses to answer a question or section, note “refused” and 
move on.  We have found that it is very rare for a subject to refuse to answer the 
questions, and this can be minimised by repeatedly assuring the subject of the 
confidentiality of the interview.   For some questions, a response card should be used 
to assist recall.  Use of the response cards for the instrument are described in the 
relevant sections below. 
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Preamble  
If the MAP is used for treatment programme outcome monitoring it is recommended 
that the following is conveyed to the subject. 
 
 1.  “We are gathering information from all of our clients to help learn more 
about how people respond to treatment and how we can make our 
services more effective”. 
 
 2.  “I am going to ask you to complete a form with me which asks about 
your substance use, and various aspects of your life during the past 30 
days. The information will remain confidential and will only be used for 
evaluation purposes”.  
 
 As implemented in practice, subjects may be asked to sign a consent form for 
participating in the study or outcome monitoring programme.  Please note that 
following good research practice it is important to inform subjects that they can 
refuse to answer any question.   
 
Sect ion A:  Management  In format ion  
 As required, the MAP interview may contain a brief introductory section to 
record the subject’s demographic details, treatment setting, referral details and the 
client’s interview point (for example intake, 3 months, 6 months or 12 months after 
intake or a t departure from the index treatment, and 3,6 and 12 months after 
departure).  This content of this section will reflect local concerns and research 
applications. 
  
Sect ion B :  Substance use 
This section contains a list of drug types.  The example instrument shown in Part IV 
lists alcohol, heroin, illicit (non-prescribed) methadone, one type of benzodiazepine, 
cocaine hydrochloride (powder), cocaine in smokable form (crack/rock) cocaine and 
amphetamines. Please note that other substances can be added according to clinical 
and research requirements. For each, the MAP asks the subject to recall: (i) the total 
number of days used in the past month; (ii) the typical amount used across a day 
when using; and (iii) their main route(s) of drug use administration.   Introduce the 
section by telling the subject that you want to begin by looking at their use of 
different substances in the past month.  State that you will take the last month to be 
the past  30 days beginning f rom yesterday.  We take this to be an approximate 
month (ie. 30 days divided by 7 = 4.29 weeks).   Complete section B as follows: 
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1.  Show Card 1 and ask the subject to recall the number of days on which he/she 
used alcohol in the past month.  Card 1 has been prepared to assist the subject to 
recall this.    
 
      Card 1  
 Every day . . . . . . .    30 
 6 days a week . . . .  26 
 5 days a week . . . . 21 
 4 days a week . . . . 17 
 3 days a week . . . . 13 
 2 days a week . . . . 9 
 Seven days . . . . . . 7 
 Six days . . . . . . . . . 6 
 Five days . . . . . . . . 5 
 Four days . . . . . . .  4 
 Three days . . . . . . . 3 
 Two days . . . . . . . . 2 
 One day only . . . . . 1 
 Some other number __ 
 None . . . . . . . . . . . 0 
 
 e.g. Subject estimates alcohol use to be “two days per week” in the past 
month.  Enter  9 in the days used column on the alcohol row (2 x 4.29 = 
8.6) 
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SCORING NOTES 
 
For example, a client estimates the frequency of their alcohol use to be 
“two days per week” in the past month.  Enter  9 in the days used 
column on the alcohol row (2 x 4.29 = 8.6). 
 
It is important to note that the MAP records the total number days on 
which the subject used each drug type, not the number of times (e.g. 
hits; joints, pipes, etc.)  they have used in total .  It is also important to 
note that Card 1 is only a guide to facilitate completion.  If, for example, 
the subject’s use of a substance has been irregular in the past month - 
which might be quite likely for crack/rock cocaine - then it is probably 
advantageous to record what the subject says ve rba t im .  The number of 
days can then be calculated later.   
 
e.g.  Subject estimates crack use in the past month to have been every 
day for the past 7 days; then at weekends only.  Either enter this pattern 
in the box or sum the total days if you prefer. In this example days of 
crack use would be: 7 + 6 = 12 .  
 
 
2. After the total days of use has been entered, ask the subject to think of a 
typical day when they used in the past month, and estimate the total amount 
consumed across the day ( i .e. the morning, afternoon and evening).   
 
SCORING NOTES 
 
For example, for alcohol enter the amount verbatim, either as named 
drinks or standard units of ethanol. 
e.g. typical drinking estimated to be: 2 x normal large can ordinary 
strength lager lunchtime, plus 4 x large can super-strength lager across 
the evening. [A normal large can (15 ¾ fl.oz) of lager beer is about 1.5 
units and a similar size super-strength can is about 3.5 units, totalling 
some 17 units for the day] 
 
For illicit substances,  enter verbatim as well, either in total amount take 
in the typical day or in money equivalents.  
 e.g.     “Half a gram” a day of heroin; or £50 
Obviously, the accurate measurement of the quantity of illicit substances 
is difficult to do and this is a proxy only. 
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3. Some subjects may have difficulty with recall of substance use in the past  
 month, particularly if their use has been highly irregular.  If this is the case, the 
quickest alternative is to use an averaging method over the three most recent days 
on which the subject used, (or two if less than three days used) , as follows: 
  (i)  ask subject to recall most recent day when used and record amount 
consumed across that day;  
 (ii)  then ask subject to recall the next previous day used and record amount. 
 (iii)   then ask subject to recall the next previous day used and record amount. 
 
The mean amount consumed across these three recent days can be calculated later. 
 
4.  Repeat procedure for each drug type listed.  For methadone, the formulation 
must be described, i.e. liquid/tablets/ampoules.  If the subject has taken more 
than one formulation enter verbatim (e.g. 40 ml of mixture + 10mg ampoule).  
For benzodiazepines  enter the drug name and amount; if the subject has used 
several benzodiazepine types enter the main ones only.  Note that the example 
MAP shown in Part IV lists one benzodiazepine only.  Space can be added for 
others as required. 
 
7.  Ask the subject to recall the routes of administration in the past month.  Enter 
the numbers from the box above the grid. 
e.g. Route used heroin was by injection; enter 4 in box.  Route used 
benzodiazepine was oral (enter 1) and by injection (enter 4). 
 
Sect ion  C:  Hea l th  R isk  Behav iour 
Items C1-C5 ask about the frequency of injecting, sharing needles and syringes and 
having unprotected (non-condom) penetrative sex during the past month. 
 
Item C1  If subject has injected drugs during the past month, use Card 1 again to 
assist recall of total number of days injected. 
 
Item C2  Enter the total number of injections across a typical day.  If the subject 
has difficulty recalling this, follow the procedure described in the drug 
grid and ask for the three most recent days when she/he has injected 
and enter the number of injections on each of these days. 
 
Item C3  This asks the subject to estimate the total number of times she/he has 
used a needle and syringe in the past month which has been used by 
someone else.  
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Ask the respondent if they have had penetrative sex in the past 30 days.   
 
Item C4-C5 These concern risky sexual behaviour.  For the purposes of the MAP we 
are focussing on penetrative sex (i.e. vaginal or anal) only.  Given the 
nature of these items, it is advisable to state in a preamble that the “next 
questions are very personal and are about your sexual behaviour.  Please 
remember that we ask these questions to all our clients”  
 
Sec t ion  D:  Hea l th  Symptoms 
Phys ica l  hea l th  - i tems D1a -D1j  
This item contains 10 physical health problems in 6 areas (general, injection-related, 
gastro-intestinal, cardio-vascular, musculo-skeletal, and neurological).  Ask the 
subject to think back over the past month, and show subject Card 2 which lists the 
frequency of experiencing each symptom (never, rarely, sometimes, often, always).  
Read out each symptom to the subject and tick the box to indicate frequency of 
experiencing it in the past month.    
 
Card 2 
 
Never 
 
Rarely 
 
Sometimes 
 
Often 
 
Always 
 
SCORING NOTES 
Items on the physical health scale are scored as follows: 
Never = 0 ; Rarely = 1; Sometimes = 2; Often = 3; Always = 4 
 
The scale scored by summing the item weights (0-4); the total can 
therefore range from 0-40. 
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Psycho log ica l  hea l th  - i tems D2a -D2j 
This section contains 10 items.  The first 5 measure symptoms of anxiety; the second  
five measure depressive ideation. Use Card 2 again to help subject assess frequency 
of having these feelings and experiences in the past month. 
 
 
SCORING NOTES 
Items on the psychological health scale are scored in the same 
way as the physical health scale:  
Never = 0 ; Rarely = 1; Sometimes = 2; Often = 3; Always = 4 
 
The scale scored by summing the item weights (0-4); the total can 
therefore range from 0-40. 
 
 
Sec t ion  E :  Persona l/soc ia l  funct ion ing  
This final section addresses three areas: relationship problems, employment and 
illegal activity. 
 
Re la t ionsh ips  
Item E1-E6:  Concern contacts and conflicts between the subject and her/his 
partner(s), relatives, children up to 18 years and friends or acquaintances.  Contacts 
means face-to-face interactions or telephone calls.  The items refer to conflicts by 
which we mean serious arguments; verbal abuse and/or violence and not routine 
differences of opinion.  Enter the number of days experiencing conflict with 
partner(s), relatives and acquaintances in the boxes.  If subject does not have any 
relatives or report having any friends or acquaintances in the past month, move to 
the next item. 
 
SCORING NOTES 
After recording both the number of days of contact and, of these, 
the number of conflict days scoring is as follows:  
                                  conflict days 
                            ---------------   X 100 = % time in contact 
                               contact days 
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Employment  
Item E7: A paid job will include casual work as well as formal contract work. Enter the 
number of days the subject had one or more jobs in the past month.  Days in 
employment include days attended as well as holidays (annual leave and public 
holidays) and other paid days where the subject was not at work (e.g. training).  Item 
E8:  Enter any days missed from the subject’s job through sickness and unauthorised 
absence (i.e. unauthorised absence being an absence which has not received prior 
agreement by the employer). Enter this number, ensuring it does not exceed 30 days.  
Item E9: Concerns days of formal unemployment during the past month.  By 
“unemployed” we mean that the subject was not in paid work or in full-time 
education.  The subject may or may not be receiving state benefit.  Include long-term 
sickness and disability as days of unemployment. 
 
I l l ega l  ac t i v i t i es 
The final section of the MAP concerns illegal activities undertaken in the past month.  
This is a sensitive area and the interviewer should re-state that the interview is 
confidential.  A prompt card (Card 3 ) should be used and this lists eight categories of 
illegal activities. 
 
Card 3 
 Selling drugs 
 
 Fraud/forgery 
  
Theft from a property  
 
 Theft from a person 
 
 Shoplifting 
 
 Theft from a vehicle 
 
 Theft of a vehicle 
 
 Other theft (specify) 
 
 
Some users may wish to add additional crime types for certain applications (e.g. 
driving a car whilst under the influence of alcohol or other drugs; domestic violence; 
etc.) 
 
Item E10:  For each crime ask the subject whether they have done this at any time in 
the past month and enter a T in the box to indicate “yes”, or a X to indicate “no”.  If 
“yes” use Card 1  to assist recall of the total number of days the subject has 
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committed each offence in the past month.  Then ask subject to estimate number of 
times committed on a typical day.  For some subjects certain crimes may be 
committed only on one occasion.  In this situation, simply enter 1 day in the days 
committed box and 1 in the time on typical day box.   
 If the subject has difficulty in estimating the typical number of times 
committed an offence, follow the averaging procedure as described previously and 
record the number of times committed on the three most recent days. 
 
SCORING NOTES 
Items on the crime involvement section (number of days and number of 
times on a typical day) can be used as individual scores or the product 
of the two taken as an estimate of the total number of crimes 
committed.   
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PART I I :  F IELD TESTING INFORMATION  
 
In this section, the reliability and validity of the MAP is described from our field 
testing studies.   
 
Re l i ab i l i t y  and  va l id i t y  assessments  
These assessments were made on a sample of 240 clients of the Maudsley treatment 
services.  Five objectives were set for the development and testing of the instrument: 
(i) good content and face validity (informed by a review of the relevant literature 
research summarised above); (ii) brief administration; (iii) simple scoring with clear 
interpretation; (iv) acceptable reliability; and (v) acceptable concurrent validity (where 
such assessment was feasible in the study).  
 Two male and two female researchers and two male and two female clinical 
nurses acted as interviewers for field testing.  Stratified subject recruitment was used 
to achieve a sample of 160 DUs (80 in community and 80 in-patient) and 80 AUs (40 
in community and 40 in-patient) with each interviewer recruiting 30 subjects (20 DUs 
and 10 AUs).  
 The community programmes were an opioid substitution and detoxification 
service for DUs, and an assessment, brief intervention and detoxification service for 
AUs.  The two in-patient programmes were a four-week detoxification and relapse 
prevention service for DUs and a 10-day assessment and detoxification service for 
AUs.    A three-day interval was selected as the most practical for the test-retest 
study.  A single two-hour training session inducted the interviewers into the use of 
the questionnaire.  Meetings were held during the course of field testing to discuss 
and resolve any difficulties encountered with the protocol.  Concurrent validity was 
assessed for the following measures: self-reported drug use, physical and 
psychological health symptom scales and the measures of relationship conflict. 
Additional items from relevant instruments for comparative purposes were added to 
the researcher-administered interview with 95 subjects.  
 
A three-day retest interval was selected as the most practical for the reliability study. 
The test-retest reliability of the instrument was assessed across the two client groups 
(DUs and AUs), the two interviewer groups (researchers and clinician nurses), and the 
two treatment settings (community and in-patient treatment).    
 The intra-class correlation coefficient (ICC) was used as the index of test-retest 
reliability (Bartko 1966).  ICCs were calculated as ratios of variance components using 
a fixed-effects analysis of variance. A  general case ICC formula, described by Shrout 
and Fleiss (1979) in which each subject is rated by each of a set of k  judges, was 
adapted for the present design.  Three ICCs were computed for each outcome 
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measure and scale: (i) an overall coefficient corrected for error attributable to intra 
and inter-subject variability across the test and retest interview; (ii) a coefficient to 
assess the impact on reliability due to interviewer type (ie. researcher or clinician); 
and (iii) a coefficient to assess variation in reliability attributable to the four 
interviewers within each of the two professional groups.  F-ratios for the second and 
third ICCs were computed to assess for significant differences from the overall ICC.  
It has been suggested that an ICC above 0.75 indicates excellent reliability; 0.65-
0.74 good reliability; 0.40-0.60 fair, and below 0.40 poor reliability (Fleiss 1991).  
Test-retest reliability of categorical measures was assessed with Cohen’s Kappa (5 ) 
(Bishop, Finberg & Holland 1975).  A K of 0.40 is suggested to be a minimum 
acceptable value, with a value of 0.60 or above indicating good to excellent reliability 
(Landis & Koch 1977).  
 It was also feasible to assess the concurrent validity of the following measures: 
self-reported drug use, the physical and psychological health symptom scales and 
the measures of relationship conflict.   
 
F ie ld  tes t ing  resu l ts  
The items in the MAP were found to be highly acceptable to a majority of the clients.  
There were 23 non-responses (where a client could not recall their behaviour or 
declined to do so) by 16 clients.  The average completion time for the test interview 
was 11.7 minutes (s.d. = 3.8;  95% confidence interval [CI] = 11.2 - 12.2 minutes; 
range =  6-27 minutes).  Average completion time for the clinician interviews was 
greater than for interviews by the researchers (12.4 minutes [s.d. = 3.9] versus 11.1 
minutes [s.d. = 3.7]; F [1,232] = 5.84; p < 0.05).    
 The personal and demographic characteristics of the sample are shown in 
Table 1.  AUs in in-patient treatment were older than the DUs in this setting and were 
also older than AUs treated in the community programme (F [3, 235] = 33.10, p < 
0.0001; Student-Numan-Keuls test, p < 0.05).  There were few differences in scores 
on the MAP between male and female clients across all the problem domains. 
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Table  1 :  Character is t i cs  o f  the  sample  by  main  problem substance   
and t reatment  set t ing (n  = 240) 
 
 
Demographic characteristic 
Primary problem drug 
users 
 Primary problem alcohol 
users 
 Community  
(n = 80) 
In-patient 
(n = 80) 
 Community  
(n = 40) 
In-patient 
(n = 40) 
% Female  37.5 37.5  27.5 25.0 
Average age (s.d.) † 31.0 (6.7) a,b 32.6 (7.8) c,d  42.7 (9.8)a,c 43.2 (10.3) b,d 
% non-white UK ethnic group  10.0 11.3    5.0  7.5 
% in relationship/past month 63.8 50.0  45.0 50.0 
% unemployed in past month 83.8 86.3  85.0 82.5 
 
† Groups sharing the same superscript letter are significantly different via post -hoc Student-Numan-Keuls test (p  < .05). 
 
Substance use. The substance use profile of the DUs before treatment is shown in 
Table 2.  There were no observed differences in the frequency and intensity of 
substance use between the in-patient and community treatment groups (non-
significant t values did not exceed 1.24 for any pairwise comparison; p > 0.05).   
 
Table  2 :  Average number  of  days  of  substance use and  
typical daily amounts reported by problem drug users during past 30 days  
before  intake to  t reatment  (n  =160)  
 
Substance use in past 30 days  
(number of users) 
Percent  
days used (s.d.) 
Amount used on 
typical day (s.d.) 
Illicit heroin  (n = 136) 77.4 (32.6) 0.4g (0.3) 
Prescribed  methadone  (n = 103) 94.9 (15.8) 48.5mg (26.7) 
Non-prescribed methadone  (n = 35) 47.3 (38.1) 49.6mg (35.5) 
Alcohol (n =90) 57.8 (38.4) 11.4 units (9.9) 
Prescribed benzodiazepines (n = 42) 
             - Valium (n = 33) 
             - temazepam (n = 9) 
 
87.0 (26.9) 
71.9 (42.8) 
 
31.8mg (19.2) 
38.3mg (26.0) 
Non-prescribed benzodiazepines (n = 31 ) 
             - valium (n = 19) 
             - temazepam (n = 12) 
 
51.4 (36.8) 
61.4 (38.1) 
 
50.3mg (51.9) 
32.5mg (21.2) 
Cocaine hydrochloride (n = 13)  33.8 (32.8) 1.2g (1.0) 
Cocaine base (crack)  (n = 53) 44.9 (41.3) 0.55g (0.4) 
 
 In order to assess the validity of self-reported drug use, the 64 DUs who 
participated in the concurrent validation interview were asked if they had used 
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heroin, methadone, benzodiazepines or cocaine during the 48-hour period before 
intake. Results from urine drug screening using homogenous Enzyme Multiplied 
Immunoassay Tests (EMIT), conducted as part of the treatment intake procedure, 
could be traced for 56 of these clients (88%) and these results are shown in Table 3.   
  The cut-off for distinguishing positive from negative samples (test sensitivity) 
for EMIT assays was set at 300ng/ml for each the four drug types tested. 
Concordance for each substance was calculated as the percentage of clients who 
reported use in the test period who tested positive plus the percentage of clients who 
did not report use and who tested negative, divided by the total number of tests 
conducted.  
 
Tab le  3 :  Va l id i ty  o f  se l f-reported drug use during 48 hours before intake  
to  t reatment  (n  = 56)  
 Concordance (%)  Disagreement with urinalysis  (%) 
 
Drug type  
(Self-report agrees 
with test result) 
kappa * False negative  
(self report negative, 
test result positive) 
 False positive  
(self report positive, 
test result negative) 
Heroin  93 .74 2  5 
Methadone 84 .65 11  5 
Cocaine 93 .76 5  2 
Benzodiazepines 91 .79 5  4 
 
* All kappa coefficients significant at p  < .001 
 
 Few problems were encountered by the clients in estimating their frequency 
and  intensity of use and their usual route of administration.  Among the DUs, 74% of 
the heroin users endorsed one of the seven frequency expressions from the response 
card,  while 26% reported some other pattern.  Twenty-two percent of crack users 
reported some other pattern.  For the AUs, 15% reported some other pattern for their 
drinking frequency.   Overall, the AUs consumed alcohol on an average of 82% of 
days (s.d. = 3.5%), with an average of 28.1 units (s.d. = 1.9 units) on a drinking day.  
Use of the other substances assessed was rare.  Just two of these clients reported 
smoking heroin on 1 and 2 days in the past month.   Fifty-seven percent (n = 91) of 
the DUs reported injecting during the previous month.  These clients injected drugs 
on 80% of these days (s.d. = 30.6) and injected on average 2.7 times on a typical day 
(s.d. = 2.0).  In-patient clients reported a higher level of injecting frequency in the 
previous month than the community treatment clients (54% of days in the month 
before intake [s.d. = 47.1) and 37% [s.d. = 43.5] respectively; t [158] = -2.29; p < 
0.05).  
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Health risk behaviour.  The proportion of injecting DUs who reported sharing 
needles/syringes in the past month before intake to treatment was 16.5% (n = 15).   
This proportion is similar to reports from the NTORS sample (Gossop et al. 1997a) 
and falls within the upper range reported by the treatment incident reporting 
databases in the UK .  The average number of sharing occasions for these clients was  
5.5 (s.d. = 7.4; range 1-30).  For risky sexual behaviour,  44% of the DUs (n = 71) 
reported having had penetrative sex without using a condom in the 30 days before 
intake to treatment.  These clients had sex when not using a condom with an average 
of one partner (s.d. = 0.6; range 0 - 4) and had sex on average 9.3 times (s.d = 
10.1).  The proportion of AUs reporting penetrative sex was 36% (n = 29).  These 
clients had sex when not using a condom on an average with one partner (s.d. = 0.6; 
range 0 - 3) and had sex on an average of 5.1 times (s.d. = 6.6).   
 
Physical and psychological health.  Pre-treatment mean scores from the physical and 
psychological health scales are shown in Table 4.  Scores on the physical health scale 
were approximately normally distributed (mean = 15.5; s.d. = 7.3; median = 15.0; 
range = 0-34).  The internal reliability of the health scale was satisfactory (alpha = 
0.79).  Higher means were observed for the AUs (17.1, s.d. = 7.8) than DUs (14.7, 
s.d. = 6.9)(F [1,236] = 6.37, p < 0.05).  Whilst means for the DUs were similar in the 
two treatment settings, the AUs in in-patient treatment reported higher scores than 
either the DUs or the community AU group (F [1,236] = 9.09, p < 0.01).   Means on the 
psychological health scales were also approximately normally distributed.  The mean 
score on the anxiety scale for the whole sample was  8.5 (s.d. = 4.8; median = 9.0; 
range = 0-20) and the mean for the depression scale was 9.3 (s.d. = 5.2; median = 
9.0; range = 0-20).  Internal reliability of the anxiety and depression scales were 
good (alpha = 0.88 and 0.86 respectively).   
 There were no significant group differences on the depression scale.  For the 
anxiety scale, the AUs scored higher than the DUs, with means of 9.9 (s.d. = 4.6)  
and 7.7 (s.d. = 4.8) respectively (F [1,236] = 10.98, p < 0.01).   
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Table 4: Pre-treatment scores on physical and psychological health and relationship 
conf l i c t  sca les  by  t rea tment  group and set t ing (n  = 240)   
 
 
Measure  
Problem drug users  Problem alcohol users F ratios (1,236) 
 Community  
(n = 80) 
In-patient 
(n = 80) 
 Communit
y  
(n = 40) 
In-patient 
(n = 40) 
Group Setting 
Physical health  14.9 (6.9) 14.4 (6.9)  14.4 (8.1) 19.8 (6.5) 6.37 * 6.50* 
Anxiety  7.7 (4.7) 7.8 (5.0)  9.0 (4.6) 10.8 (4.5) 10.98 ** 1.97 
Depression  8.9 (5.1) 9.4 (5.6)  9.5 (5.0) 9.7 (4.7) 0.40 0.24 
 
 
 The concurrent validity of the physical and psychological health measures was 
assessed against the number of self-reported days in the month preceding intake to 
treatment on which the client experienced medical problems and anxiety and 
depressive thoughts, using items adapted from the ASI (McLellan et al. 1992a).   
Pearson correlations were as follows: health scale and days of medical problems (r = 
0.73; p < 0.0001);  anxiety scale and days experienced anxious thoughts (r = 0.74; p 
< 0.0001), and depression scale score and days experienced depressive thoughts  (r  
= 0.69; p < 0.0001).   
 
Relationship conflict.  Table 5 shows the percentage of contact time that the clients 
reported having serious conflict with partners, relatives and friends.  On average, 
clients from in-patient treatment reported more conflict with their partner (F [1,236] = 
4.54; p < 0.05).  DUs were also more likely than the AUs to report conflict with their 
relatives (F [1,236] = 5.16; p < 0.05).  There were no reported differences in conflict 
with friends. The relationship stressors sub-scales of the Adult Form of the Life 
Stressors and Social Resources Inventory (LISRES, Moos 1988a) were included in the 
concurrent validity interview (n = 95).   
 Each five-item scale from the LISRES records the frequency with which the 
respondent has experienced specific stressors such as, “Is he or she critical or 
disapproving of you?” rated on a five-point scale (1 = never to 5 = all the time), with 
similar items used to assess stressors in two other relationship domains.  Pearson 
correlations between the mean scores on the LISRES scales and the conflict measures 
(n = 95) were high: partner stressors and partner conflict (PC) (r =  .76; p < 0.0001), 
relatives stressors and relatives conflict (RC)  (r =.77; p < 0.0001), and friends 
stressors and friends conflict (FC)  (r = .70; p < 0.0001).   
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Table 5: Pre-treatment scores on physical and psychological health and relationship 
conf l i c t  sca les  by  t reatment  group and set t ing (n  = 240)   
 
 
Measure 
Problem drug users  Problem alcohol users F ratios (1,236) 
 Community  
(n = 80) 
In-patient 
(n = 80)  
Community  
(n = 40) 
In-patient 
(n = 40) 
Group Setting 
Partner conflict 20.7 (36.3) 9.5 (23.9)  18.1 (33.6) 11.1 (30.2) 0.20   5.28 * 
Relatives conflict 10.7 (25.5) 12.9 (28.7)  2.8 (9.0) 6.3 (14.5)    1.60 * 1.21 
Friends conflict 5.4 (17.3) 10.5 (26.3)  8.0 (23.6) 2.3 (7.4) 0.67 0.09 
     p< .05 
 
Employment.  Substantial employment difficulties were reported. The rate of formal 
unemployment among the DUs was 85% (n = 136).  Only 33 DUs (21%) reported 
having had paid work.  For these clients an average of 13% (s.d. = 29.9) of work days 
were missed through sickness or other absence.   Amongst the AUs, 84%( n = 67) 
were unemployed before treatment.  Fifteen percent (s.d. = 29.6) of working days 
were reported as being missed due to sickness or unauthorised absence.  
 
Crime.   Eighty-nine (56%) of the DUs reported committing a total of 5,630 individual 
offences during the past month.  A summary of the DUs’ involvement in selling 
drugs, shoplifting and “other crime” is shown in Table 6.  Reported criminal 
behaviour during the past month was very rare amongst the AUs.  Only one client 
reported that they had shoplifted on a single day in the month.  
 
Table  6 :  Cr ime invo lvement  in  past  30 days  amongst  problem drug  
users  before  intake to  t reatment  (n  = 160)   
 
 
Offence type 
 
n (%) 
 
% days 
committed  
 Average 
number of 
offences  
Total number 
of offences 
Selling drugs 24 (15) 42.6 (34.8)  93.0 (127.9) 2,233 
Shoplifting 40 (25) 47.8 (40.3)  42.2 (61.4) 1,686 
Other crime † 25 (16) 40.9 (37.0)  68.4 (112.9) 1,711 
 
 Note:  Other crime category composed of the following offence types:  theft from a property,   
  theft from a person, and theft from or of a vehicle, and fraud/forgery. 
   
Re tes t  admin is t ra t ion  and  re l i ab i l i t y 
 MAP interviews were readministered to clients after 3.1 days (s.d. = 2.7).  Table 
6 presents the ICC reliability coefficients for the frequency and intensity of substance 
use.  ICCs are shown for the overall sample and for those clients reporting use of 
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each substance during the month before treatment.  Test-retest reliability for all 
substances was high, averaging .94 overall and .88 for clients reporting use.   For the 
users of each substance, ICCs for frequency were highest for heroin (0.92).  The 
lowest ICCs, still within a margin reflecting excellent reliability, were for crack cocaine 
users (percentage of days used = 0.77 and intensity 0.77).  ICCs to assess variability 
in test-retest reliability between and within the two interviewer professional groups 
were uniformly high (averaging 0.84).  F ratios for differences from the overall ICC 
did not exceed 1.29 for any pairwise comparison (p > 0.05).   For the usual route of 
drug administration, test-retest reliability was also excellent.  Kappa coefficients 
were as follows: heroin (0.93); methadone (1.0), benzodiazepines (1.0) and cocaine 
(1.0).   Table 8 shows the ICCs for the health risk, health problems, relationship 
conflict, employment and crime measures.  Coefficients were again uniformly high 
(averaging 0.81) and F ratios for differences from the overall ICC did not exceed 1.84 
for any pairwise comparison (p > 0.05). 
  
Table 7: Three day test-retest ICC reliability estimates for substance use (n = 240) 
 
 
Drug  
Percent days used   Intensity on using day 
 Overall ICC (95% 
CI) 
Users ICC 
(95% CI)  
Overall ICC 
(95% CI) 
Users ICC 
(95% CI) 
Heroin   0.96 (0.95 -0.97) 0.92 (0.89-0.95)  0.96 (0.95-0.97) 0.95 (0.93-0.97) 
Illicit methadone  0.89 (0.86 -0.92) 0.91 (0.84-0.96)  0.90 (0.87-0.92) 0.84 (0.72-0.92) 
Prescribed methadone  0.97 (0.96 -0.98) 0.79 (0.71-0.85)  0.96 (0.94-0.97) 0.92 (0.88-0.94) 
Cocaine hydrochloride  0.89 (0.86 -0.92) 0.91 (0.70-0.98)  0.90 (0.87-0.92) 0.79 (0.40-0.96) 
Cocaine base (crack)  0.96 (0.95 -0.97) 0.77 (0.64-0.87)  0.89 (0.86-0.91) 0.77 (0.64-0.87) 
Pres. benzodizepines  0.96 (0.95 -0.97) 0.92 (0.85-0.96)  0.94 (0.92-0.95) 0.86 (0.75-0.93) 
Illicit benzodiazepines  0.91 (0.88 -0.93) 0.83 (0.67-0.92)  0.84 (0.80-0.88) 0.78 (0.59-0.90) 
Alcohol (drug clients)  0.94 (0.91 -0.95) 0.95 (0.93-0.97)  0.95 (0.93-0.96) 0.93 (0.89-0.95) 
Alcohol (alcohol clients)  0.95 (0.94 -0.96) 0.94 (0.92-0.96)  0.96 (0.95-0.97) 0.95 (0.93-0.97) 
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Table  8 :  Three day  test-retest  ICC re l iab i l i ty  es t imates  (95% CI )  
fo r  hea l th  r i sk  behav iour ,  hea l th  prob lems,  re la t ionsh ip  conf l i c t , 
employment  and cr ime  (n  = 240)  
Measure Problem  
drug users 
Problem  
alcohol users 
Times “shared” needles 0.97 (0.95-0.98) - 
No. of sexual partners 0.92 (0.90-0.95) 0.96 (0.91-0.98) 
Times non-condom sex 0.88 (0.82-0.91) 0.82 (0.64-0.92) 
Physical health problems  0.86 (0.82-0.89) 0.89 (0.85-0.93) 
Anxiety symptoms 0.88 (0.84-0.91) 0.87 (0.81-0.91) 
Depression symptoms 0.86 (0.82-0.89) 0.92 (0.89-0.95) 
Partner conflict 0.83 (0.78-0.87) 0.91 (0.89-0.93) 
Relatives conflict 0.78 (0.72-0.83) 0.77 (0.69-0.84) 
Friends conflict 0.67 (0.59-0.74) 0.77 (0.68-0.83) 
% days worked 0.99 (0.99-0.99) 0.99 (0.99-1.0) 
No. of work absences 0.98 (0.96-0.99) 0.98 (0.94-0.99) 
% days unemployed 0.89 (0.86-0.92) 0.96 (0.94-0.97) 
% days drug selling 0.94 (0.93-0.96) - 
% days shoplifting 0.89 (0.87-0.92) - 
% days other crime 0.85 (0.81-0.89) - 
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MAUDSLEY ADDICTION PROFILE (MAP) 
 
 
 
SECTION A: MANAGEMENT INFORMATION 
 
Include the study specific information as required (e.g. participant identification, programme codes; interview point) 
 
 
 
SECTION B: SUBSTANCE USE  
 
CARD 1 
 
None 1 day 
only  
2 days 
only 
3 days 
only 
1 day a 
week 
2 days 
a week 
3 days 
a week 
4 days 
a week 
5 days 
a week 
6 days 
a week 
Every 
day 
Some 
other 
number 
0 1 2 3 4 9 13 17 21 26 30  
 
CARD 2 
 
Oral Snort/sniff Smoke/chase Intravenous Intramuscular 
1 2 3 4 9 
 
 
a. Enter number of days used in past 30 days [Card 1] – enter “0” for no use;  
b. Enter amount used on a typical day in the past 30 days [verbatim]  
c. Record route(s) of administration [Card 2] 
 
 
SUBSTANCE DAYS USED AMOUNT USED ON TYPICAL DAY ROUTE(S) 
B1.  Alcohol 
 
  
 
 
B2. Heroin 
 
 
 
 
 
 
 
B3. Illicit methadone 
 
 
 
 
  
B4. Illicit benzodiazepine  
 
 
 
Drug: 
 
B4. Cocaine powder 
 
 
 
 
  
B5. Crack cocaine 
 
 
 
 
  
B6. Amphetamine 
 
 
 
 
  
B7. Cannabis 
 
 
 
  
B8. Other: 
 
   
 ------------------------------------  
 
  
 ------------------------------------  
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SECTION C: HEALTH RISK BEHAVIOUR 
 
 
If no illicit drugs injected in the past 30 days, skip to sexual behaviour questions 
 
 
C1. Days injected drugs in the past 30 days [card 1]   
 
Days 
   
 
C2. Times injected on a typical day in the past 30 days   
 
Times  
   
 
C3. Times injected with a needle/syringe already used by someone else  
 
Times  
 
 
If no penetrative sex in the past 30 days, skip to Section D 
 
 
C4. Number of people  had sex with and not used condom  
 
People  
   
 
C5. Total number of times had sex with and not used condom  
 
Times  
 
 
 
 
 
SECTION D: HEALTH SYMPTOMS  
 
CARD 3 
 
Never  Rarely  Sometimes Often  Always 
0 1 2 3 4 
 
 
D1. How often experienced the following physical health symptoms 
 
 
 
 Never 
(0) 
Rarely 
(1) 
Sometimes 
(2) 
Often 
(3) 
Always 
(4) 
a. Poor appetite  r r r r r 
b. Tiredness/fatigue r r r r r 
c. Nausea (feeling sick) r r r r r 
d. Stomach pains r r r r r 
e. Difficulty breathing  r r r r r 
f. Chest pains r r r r r 
g. Joint/bone pains r r r r r 
h. Muscle pains r r r r r 
i. Numbness/tingling r r r r r 
j. Tremors/shakes r r r r r 
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D2. How often experienced the following emotional or psychological symptoms [card 3]  
 
 
 Never 
(0) 
Rarely 
(1) 
Sometimes 
(2) 
Often 
(3) 
Always 
(4) 
a. Feeling tense r r r r r 
b. Suddenly scared for no reason r r r r r 
c. Feeling fearful r r r r r 
d. Nervousness of shakiness inside r r r r r 
e. Spells of terror or panic r r r r r 
f. Feeling hopeless about the future r r r r r 
g. Feelings of worthlessness r r r r r 
h. Feeling no interest in things r r r r r 
i. Feeling lonely r r r r r 
j. Thoughts of ending your life r r r r r 
 
 
 
 
SECTION E: PERSONAL/SOCIAL FUNCTIONING 
 
 
 
If not in a relationship in the past 30 days, skip to relatives questions 
 
 
E1. Days had contact with partner in the past 30 days [card 1]  
      (ie. say them or talked on the telephone) 
 
 
Days 
   
 
E2. Number of these days were there was conflict with partner 
      (ie. had major arguments)  
 
 
Days  
 
 
 
If not relatives or any contact with relatives in past 30 days, skip to friends questions 
 
 
E3. Days had contact with relatives in the past 30 days [card 1]  
      (ie. say them or talked on the telephone) 
 
 
Days 
   
 
E4. Number of these days were there was conflict with relatives 
      (ie. had major arguments)  
 
 
Days  
 
 
If not friends or any contact with friends in past 30 days, skip to Section E7 
 
 
E5. Days had contact with friends in the past 30 days [card 1]  
      (ie. say them or talked on the telephone) 
 
 
Days 
   
 
E6. Number of these days were there was conflict with friends 
      (ie. had major arguments)  
 
 
Days  
 
 
     
 
40
 
 
E7. Number of days of paid work in past 30 days [card 1]   
 
Days  
   
 
E8. Days missed from work because of sickness or unauthorised absence                                      
      in the past 30 days 
 
 
Days 
   
 
E9. Days formally unemployed in the past 30 days  
 
Days  
 
 
 
CARD 4 
 
 
Selling drugs  Fraud/forgery  Shoplifting Theft from a 
property  
Theft from a 
vehicle 
Theft of a 
vehicle 
Other 
crimes 
 
 
 
E10.  Crimes committed in the past 30 days [card 4 and card 1] 
 
 
 Days committed 
[card 1] 
 Number of times 
committed on a typical 
day [card 2] 
a. Selling drugs    
 
    
b. Fraud/forgery    
 
    
c. Shoplifting    
 
    
d. Theft from a property    
 
    
e. Theft from a vehicle    
 
    
f. Theft of a vehicle       
 
   Other crimes:    
   ------------------------------        
 
  
   ------------------------------    
 
   ------------------------------    
 
 
 
 
END OF INTERVIEW  
 
 
